RCM
OCUL icon

Requisite Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Requisite Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-15,000
Closed -$125K – 78
2020
Q2 		$125K Hold
15,000
– – 0.05% 60
2020
Q1 		$74K Buy
+15,000
New +$74.1K 0.03% 54

Other funds holding OCUL

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Requisite Capital Management's OCUL Position: Q3 2020 in Review

Requisite Capital Management sold out of Ocular Therapeutix (OCUL) in Q3 2020, closing a stake of 15,000 shares — an estimated $125K sold.

Requisite Capital Management first reported a position in OCUL in Q1 2020 and held it in 2 quarters. The position peaked at $125K in Q2 2020. 108 funds tracked by Wall St. Rank hold OCUL as of Q3 2020.

  • Requisite Capital Management reported no remaining Ocular Therapeutix position as of Q3 2020 after selling out during the quarter.
  • Requisite Capital Management sold 15,000 Ocular Therapeutix shares in Q3 2020, an estimated $125K.
  • Requisite Capital Management first reported a position in Ocular Therapeutix in Q1 2020 and held it in 2 quarters.
  • Requisite Capital Management's Ocular Therapeutix position peaked at $125K in Q2 2020.
  • 108 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2020.

Based on Requisite Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.